Board of Directors
Harry Hyman
Chairman
Harry Hyman is the founder and CEO of Primary Health Properties PLC (“PHP”), a FTSE 250 Index company that specialises in the ownership of property leased on a long‐term basis to healthcare providers. After graduating from Christ’s College Cambridge, Mr Hyman qualified as a chartered accountant with Price Waterhouse. In 1983 he joined Baltic PLC where he was deputy managing director, finance director and company secretary. He left to establish PHP and Nexus in February 1994. Mr Hyman is the founder of The International Opera Awards. He has been a non‐executive director of a number of listed investment trusts.
Duncan Budge
Director
Duncan Budge is chairman of Dunedin Enterprise Investment Trust plc and Artemis Alpha Trust plc, and a non‐executive director of Lowland Investment Company plc, Menhaden Capital plc and Asset Value Investors Limited. He was previously a director of J. Rothschild Capital Management from 1988 to 2012 and a director and chief operating officer of RIT Capital Partners plc from 1995 to 2011. After graduating from the University of Oxford, he spent six years with Lazard Brothers.
Colin Bond
Director
Colin Bond has been chief financial officer of the pharmaceutical company Sandoz since May 2022. He is a non‐executive director of Siegfried AG. He was previously chief financial officer of Vifor Pharma from 2016 to 2022 and he was the chief financial officer of Evotec AG from 2010 to 2016. Prior to that, he held CFO positions at several companies including Ecolab and Novelis. During his early career, he worked as a pharmacist, auditor, and management consultant for Procter & Gamble, Arthur Andersen, and PricewaterhouseCoopers LLP, respectively. He holds a BSc. in Pharmacy from the University of Aston (Birmingham) and an M.B.A. degree from London Business School. He is a fellow of the Institute of Chartered Accountants in England and Wales and a member of the Royal Pharmaceutical Society. He is a citizen of Great Britain and Switzerland.
Stephanie Léouzon
Director
Stephanie Léouzon is Managing Director in Health Care Investment Banking at Stifel. She has worked on over 100 strategic and financing transactions in the biopharmaceutical industry, with an aggregate value of over $75 billion. Mrs Léouzon joined Torreya (a Stifel company) in 2011. Previously, she was a managing director and senior adviser at Credit Suisse in London. She has also worked at Salomon Brothers, as a director of healthcare investment banking, and as a vice president in the investment banking divisions of JP Morgan and Lehman Brothers in New York. She was previously a non‐executive director of Immunovaccine Inc and Endotis Pharma SA.
Rolf Soderstrom
Director
Rolf Soderstrom has over 30 years’ strategic and operational experience in finance including M&A, fundraisings and disposals and is currently CFO of Syncona Investment Management Limited and External Independent Director of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange. From 2008 to 2018, Mr Soderstrom was CFO of BTG plc and helped drive the successful transformation of the company into a fully integrated global manufacturing and sales organisation focused on specialist healthcare. He was previously Divisional Finance Director at Cobham Plc and Director of Corporate Finance at Cable & Wireless Plc and qualified as a chartered accountant at PricewaterhouseCoopers LLP. He received a BA honours degree in History from University College London and is a member of the Institute of Chartered Accountants of England and Wales. Mr Soderstrom is a citizen of Great Britain and Finland.
Sapna Shah
Director
Sapna Shah has 20 years of investment banking experience advising UK companies, including listed REITs and investment companies, on IPOs, equity capital market transactions and mergers and acquisitions. Sapna is a non-executive director of Supermarket Income REIT plc and a non-executive director and remuneration committee member of The Association of Investment Companies (“AIC”). Sapna is a Senior Adviser at Panmure Gordon Limited and prior to this held senior investment banking roles at UBS AG, Oriel Securities (now Stifel Nicolaus Europe) and Cenkos Securities. She has previously served on the advisory committee for a private solar energy company.
Investment Team
Pedro Gonzalez de Cosio
Investment Manager
Mr. Gonzalez de Cosio is a Principal and co-founder of the Investment Manager and will manage the Company’s portfolio. During the 14 years prior to founding the Investment Manager, Mr. Gonzalez de Cosio held various positions in the structured finance divisions of Deutsche Bank and JP Morgan in New York, where he was responsible for structuring various forms of collateralised financings and derivatives for US and international clients, including several years covering clients in the life sciences industries. Mr. Gonzalez de Cosio’s prior experience also includes various positions in the investment banking division of Nomura Securities in New York, the leasing division of Société Générale in Paris, and coordinating the issuance of external debt for the Mexican Ministry of Finance. Mr. Gonzalez de Cosio earned a B.A. degree (Summa Cum Laude) in Business Administration from the University of San Diego and an M.B.A. from INSEAD in Fontainebleau, France.
Pablo Legorreta
Investment Manager
Mr. Legorreta is Founder and Chief Executive Officer of Royalty Pharma and a Principal and co-founder of the Investment Manager providing advisory oversight. Founded in 1996, Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property, with over $17 billion in royalty assets. Royalty Pharma funds innovation in life sciences, indirectly, when it acquires existing royalty interests from the original innovators (academic institutions, research hospitals, foundations and inventors) or, directly, when it partners with life sciences companies to co-develop and co-fund products in late-stage human clinical trials. Prior to founding Royalty Pharma, Mr. Legorreta spent a decade at Lazard Frères in Paris and New York where he provided cross-border merger and acquisition and corporate finance advisory services to European and U.S. corporations. Mr. Legorreta serves on the Board of Governors of the New York Academy of Sciences, and the Boards of Trustees of Rockefeller University, The Hospital for Special Surgery, The Pasteur Foundation (U.S. affiliate of the French Institut Pasteur), The Open Medical Institute, The Park Avenue Armory and Grace Church School. Mr. Legorreta founded and is currently Chairman of Alianza Médica para la Salud (AMSA), a privately-funded, not-for-profit foundation whose goal is to educate Latin American doctors and healthcare providers to improve the quality of healthcare in Latin America. Mr. Legorreta received a degree in industrial engineering from Universidad Iberoamericana (Mexico City).
Martin Friedman
Investment Manager
Mr. Friedman is a Principal of the Investment Manager, having joined in 2011. Mr. Friedman has spent the past 22 years in various positions in the healthcare finance industry, most recently as the co-head of the US life sciences banking at Bank of America/Merill Lynch. He has worked very closely with both large cap and emerging pharmaceutical, biotech, specialty pharmaceutical, device and diagnostic companies, having advised on M&A transactions and raised equity and debt capital. Mr. Friedman’s prior experience also includes his 12 years at JPMorgan, including four years at JPMorgan Partners, and several years as the Head of M&A and Collaborations at Novartis AG based in Switzerland. Mr. Friedman earned a B.A. degree in English and History from Columbia College and an M.B.A. (Honours) in Finance and Accounting from Columbia Business School.